ISELIN, N.J., Nov. 30 /PRNewswire-FirstCall/ -- Pharmos Corporation announced today that President and COO Alan L. Rubino will present at the BMO Capital Markets Focus on Healthcare Conference on Thursday, December 7, 2006 at 11:00 AM Eastern Time. The conference is taking place December 6-7, 2006 at the Millennium Broadway Hotel in New York, New York.
A webcast of Pharmos’ presentation will be available at http://www.bmocm.com/conferences/healthcare2006/webcast/default.aspx and will be archived for a limited period after the conference.
About Pharmos Corporation
Pharmos discovers and develops novel therapeutics to treat a range of indications with a focus on specific diseases of the nervous system including disorders of the brain-gut axis (GI/IBS), pain/inflammation, and autoimmune disorders. The Company’s lead product, dextofisopam, has completed Phase 2a testing in IBS, with positive effect on the primary efficacy endpoint (n=141, p=0.033). The Company plans a Phase 2b study of dextofisopam for the treatment of IBS in 2007. The Company’s core proprietary technology platform focuses on discovery and development of synthetic cannabinoid compounds. Cannabinor, the lead CB2-selective receptor agonist candidate, is undergoing Phase 2a testing in pain. Other compounds in Pharmos’ pipeline are in clinical and pre-clinical studies targeting pain, multiple sclerosis, rheumatoid arthritis and other disorders.
Safe Harbor Statement
Statements made in this press release related to the business outlook and future financial performance of Pharmos, to the prospective market penetration of its drug products, to the development and commercialization of its pipeline products and to its expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos’ filings with the Securities and Exchange Commission could affect such results.
Pharmos Corporation
CONTACT: Colin Neill, CFO, or Gale Smith, IR , both of Pharmos U.S.,+1-732-452-9556 , or Irit Kopelov, Pharmos Israel, +972-8-940-9679,Investors - John Quirk, +1-646-536-7029, Media - Janine McCargo, +1-646-5367033, both of The Ruth Group, Inc.
Web site: http://www.pharmoscorp.com//
